<DOC>
	<DOC>NCT00783406</DOC>
	<brief_summary>This study will look at the pharmacokinetics, safety, toleration and efficacy of PF-00610355 in the chronic obstructive pulmonary disease (COPD) population. The doses in this study are intended to explore the anticipated clinical dose range.</brief_summary>
	<brief_title>Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients.</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>Postbronchodilator FEV1/ FVC ratio of &lt;0.7. Post bronchodilator FEV1 of 5080% (inclusive) of predicted. Body Mass Index (BMI) of less than 35 kg/m2; and a total body weight greater that 40 kg. Current smokers, or exsmokers who have abstained from smoking for at least 6 months. Subjects having more than 2 exacerbations requiring treatment with oral steroids or hospitalization for the treatment of COPD in the previous year. History of lower respiratory tract infection or significant disease instability during the month preceding screening or during the period between screening and randomization.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>COPD</keyword>
</DOC>